Trial Profile
A Phase 1, Randomized, Placebo-and Positive-controlled Crossover Study To Determine The Effect Of Single-dose Pf-06700841 On Qtc Interval In Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Brepocitinib (Primary)
- Indications Alopecia areata; Crohn's disease; Inflammatory bowel diseases; Plaque psoriasis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Dec 2022 Results (from 5 clinical trials; NCT02310750 NCT03236493 NCT03656952 NCT02969018 NCT02974868 ) assessing Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients published in the Clinical Pharmacology in Drug Development
- 25 Feb 2019 Status changed from recruiting to completed.
- 28 Nov 2018 Planned End Date changed from 3 Dec 2018 to 6 Jan 2019.